The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the Haystack MRD test, a circulating tumor DNA (ctDNA) assay developed by Quest Diagnostics. This designation is intended to accelerate the development and approval of tools that show significant potential for addressing unmet medical needs, such as early cancer detection. ctDNA tests analyze DNA fragments from tumors that circulate in the bloodstream, offering a non-invasive way to monitor cancer, detect minimal residual disease after treatment, and potentially identify cancer at earlier stages than some traditional methods. The FDA’s recognition could pave the way for wider clinical adoption of ctDNA testing, particularly in scenarios where early intervention significantly improves outcomes.
About the Author
